SUPERSEDED Local Coverage Determination (LCD)

Dialysis Access Maintenance

L34062

Expand All | Collapse All
Proposed LCD
Proposed LCDs are works in progress that are available on the Medicare Coverage Database site for public review. Proposed LCDs are not necessarily a reflection of the current policies or practices of the contractor.
Superseded
To see the currently-in-effect version of this document, go to the section.

Document Note

Note History

Contractor Information

LCD Information

Document Information

Source LCD ID
N/A
LCD ID
L34062
Original ICD-9 LCD ID
Not Applicable
LCD Title
Dialysis Access Maintenance
Proposed LCD in Comment Period
N/A
Source Proposed LCD
N/A
Original Effective Date
For services performed on or after 10/01/2015
Revision Effective Date
For services performed on or after 02/09/2023
Revision Ending Date
01/31/2024
Retirement Date
N/A
Notice Period Start Date
N/A
Notice Period End Date
N/A
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2023 American Dental Association. All rights reserved.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Issue

Issue Description

This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations and/or Medical Necessity.

Issue - Explanation of Change Between Proposed LCD and Final LCD

CMS National Coverage Policy

Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act (SSA):

Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

CMS Publications:

CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 11: End Stage Renal Disease (ESRD):

      20.1 Noninvasive Vascular Studies for End Stage Renal Disease (ESRD) Patients

 

      30.4.2 Separately Billable Drugs.

 

      30.5 ESRD Composite Payment Rates

 

    80 Physician’s Services for Renal Dialysis Patients - General

CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 14: Medical Devices:

      10 Coverage of Medical Devices

 

    20 FDA Approval Investigational Device Exemptions (IDEs) 20.2 - Category B

CMS Publication 100-03, Medicare National Coverage Determinations Manual, Part 1:

    20.7.B1 Percutaneous Transluminal Angioplasty (PTA)20.7.D Other

CMS Publication 100-09, Medicare Contactor Beneficiary and Provider Communications Manual, Chapter 5: Correct Coding Initiative.

CMS Transmittal AB-00-44, Change Request #1118, May 2000: Medicare Coverage of Non-Invasive Vascular Studies When Used to Monitor the Access Site of End Stage Renal Disease (ESRD) Patients.

CMS Transmittal AB-00-55, Change Request #1117, June 2000: Hemodialysis Flow Study.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Arteriovenous (AV) dialysis access (AV fistula, AV dialysis graft) interventions are intended to restore and/or maintain functional patency of the AV dialysis access. These procedures encompass a number of percutaneous or open surgical procedures. Indications for interventions on an AV dialysis access include compromised flow with threatened occlusion, recent thrombosis of AV dialysis access, and management of structural abnormalities such as pseudoaneurysms. Interventions are performed on AV dialysis fistulas and grafts in order to restore adequate flow, to preserve the access' function, and avoid the need to create a new AV access. Fistulae which are not maturing as expected are also evaluated and treated with percutaneous interventions.

Percutaneous interventions to enhance or re-establish patency of a hemodialysis AV access have proven useful in extending the life of the access, reducing the need for open repair, reconstruction or replacement. The longevity and quality of life of the end stage renal dialysis (ESRD) patient are improved. This policy documents acceptable indications and limitations of coverage and other CGS requirements for dialysis access maintenance services.

Definitions:

(AV) dialysis access: A surgically-created communication between an artery and a vein used for vascular access for hemodialysis. The communication may be a direct fistula (AV fistula) (e.g. Brescia Cimino fistula), brachiocephalic fistula or an interposed conduit (AV graft) (e.g. brachiocephalic loop graft). The conduit may be an autogenous vessel or synthetic material.

Percutaneous transluminal angioplasty (PTA): An invasive procedure which, when successful, enlarges a narrowed vascular lumen. Typically, a balloon-tipped catheter is introduced percutaneously into the narrowed vessel. The balloon is inflated at the site of vascular stenosis, stretching the vessel and opening the lumen to restore adequate flow through the vessel. The balloon is removed after angioplasty.

Thrombolysis: Pharmacologic and/or mechanical dissolution of a thrombus or blood clot.

Infusion: Continuous intravascular administration of a medication containing solution lasting longer than sixty (60) minutes. Bolus injections are not considered infusions, regardless of the time required to inject the solution.

Dialysis Access: An arteriovenous dialysis access.

Embolization/ligation of collateral branch veins: AV fistulae depend on a single outflow vein to carry the flow, so that this vein can enlarge to the point it is easily punctured and has brisk flow. If branch veins are large enough to siphon off a significant amount of flow, no single vein will enlarge enough to be used. Closing off the side branches may allow the outflow vein to mature. The side branches may be closed off surgically by tying off the branches, or may be closed off by placement of occlusive material into the side branch through a catheter (embolization).

Indications:

Evaluation of Dialysis Access Dysfunction - Clinical Findings

Typically, the clinical examination provides adequate information to determine whether there is hemodynamically significant dialysis shunt dysfunction. The following clinical findings are considered diagnostically specific and appropriate indications to initiate therapies to re-establish physiologically appropriate flow in the dialysis fistula.

Venous outflow impediment clinical findings include:

  • elevated venous pressure in the AV dialysis access;
  • elevated venous/arterial ratio (static venous pressure ratio - above 40%);
  • prolonged bleeding following needle removal;
  • inefficient dialysis;
  • recirculation percentage greater than 10-15%;
  • development of pseudoaneurysm(s);
  • swelling of the extremity, face or neck;
  • development of large superficial collateral venous channels;
  • loss of "machine-like" bruit, i.e., short sharp bruit; and/or
  • abnormal physical findings, specifically pulsatile graft/fistula or loss of thrill.

Arterial inflow impediment clinical findings include:

  • low pressure in graft even when outflow is manually occluded;
  • ischemic changes of the extremity (steal syndrome); and/or
  • diminished intra-access flow.

Evaluation of Dialysis Access Dysfunction – Diagnostic Tests

If a stenosis is suspected clinically, typically a diagnostic study is required to determine the level(s) of disease and to formulate a plan for treatment. This is most commonly accomplished with a fistulagram (36901-36906).

  • Diagnostic fistulagram – with puncture of the AV dialysis access with needle or catheter placement, and diagnostic angiography of the entire AV dialysis access circuit, from the arterial anastomosis through the central veins and cava, which is performed to identify the area or areas of narrowing or occlusion that are creating flow problems for the AV dialysis access (36901-36906). This includes visualization and examination of the vena cava.

  • Diagnostic fistulagram - without directly puncturing and/or catheterizing the AV dialysis access. For instance, a fistulagram may be performed through an existing needle or sheath or via an injection of a vessel other than direct puncture of the AV dialysis access (e.g., injection of the subclavian artery through a femoral arterial puncture) (CPT code 36901-36906).

  • Diagnostic non-invasive vascular studies (CPT code 93990) performed to evaluate an AV access are reasonable and necessary in the presence of signs and symptoms of impending failure of the access sites and when the result may impact the clinical course of the patient.

Percutaneous AV Dialysis Access Maintenance and Salvage

Percutaneous AV dialysis access declotting, maintenance, or re-establishment of appropriate and adequate flow may encompass any of the procedures listed below. These need not all be performed on every dysfunctional access, but each may, under unique circumstances, be considered reasonable and medically necessary.

Mechanical and/or pharmacologic maneuvers to promote dissolution, fragmentation and/or removal of obstructing thrombotic materials (36904-36906) - includes all work necessary to remove thrombus from the AV dialysis access, including mechanical thrombolysis, mechanical removal of thrombus, as well as all pharmacological means of removing thrombus from the dialysis access (including bolus, infusion, pulse-spray etc.).

Percutaneous transluminal angioplasty (PTA): - PTA of the AV dialysis access and/or afferent and efferent vessels is not necessary for all poorly functioning AV dialysis accesses. Coverage will be considered if there is documentation supporting the presence of residual, hemodynamically significant stenosis, generally >/50 percent of the vessel diameter. There must be clear documentation of the site and extent of any hemodynamically significant stenosis. This documentation may be subjected to medical necessity review.

Venous PTA – PTA is typically necessary to treat stenoses. The stenosis is most commonly found at the level of the venous anastomosis for synthetic graft accesses, but can be found anywhere from the arterial inflow through the vena cava. Multiple stenoses are found in a significant percentage of patients. When the patient presents with a thrombosed AV access, PTA is commonly needed after the acute thrombus has been removed. The AV access often occludes because of decreased flow due to an underlying narrowing, and this narrowing must be opened in order to prevent acute re-occlusion.

For purposes of reporting, the AV dialysis access is considered a single vessel from the arterial anastomosis through the axillary vein. All PTA done within this segment of vessel is coded as CPT codes 36902, 36905, 36907, 37247-37249 used once no matter how many focal lesions are treated within this segment. All PTA within the arteriovenous dialysis access “vessel” would be coded as a single PTA, regardless of the number of stenoses treated within this segment.

For AV dialysis native fistulae, the “vessel” is defined as the inflow artery at the AV anastomosis, the AV anastomosis, and the outflow vein to the level of the axillary vein. For AV dialysis grafts, the “vessel” is defined as the inflow artery at the arterial anastomosis, the arterial anastomosis, the entire length of the graft, the venous anastomosis, and the venous outflow to the level of the axillary vein. All PTA done within these defined segments would be coded as a single angioplasty.

Angioplasty may be coded a second time if a separate stenosis is treated in a central vessel (e.g., axillary, subclavian, brachiocephalic vein or artery, or SVC). The site of, and need for, separate stenosis treatment should be clearly documented. If central venous stenoses are treated, the venous angioplasty codes 36902, 36905, 36907, and 37247-37249 should be used once to describe central venous angioplasty, even if more than one discrete central lesion must be treated.

There is one clinical situation that is an exception to the above. Arterial PTA may be necessary if there is an inflow arterial stenosis that is limiting flow through the dialysis access. If a PTA is performed at the arterial anastomosis of an AV dialysis access, it could be coded as 36902, 36905, 36907, and 37246-37249. In this instance, all PTA done within the AV dialysis access “vessel” would still be coded as a single PTA but would be coded with the arterial codes (36902, 36905, 36906, 37246-37249) instead of the venous codes (36902, 36905, 36907, 37247-37249), and the venous codes would not be used for any other angioplasty performed within the AV dialysis access vessel.” Arterial PTA codes are not submitted for simple removal of the arterial plug when performing a declot procedure.

Open Surgical AV Dialysis Access and Maintenance

  • Open surgical therapy for thrombosed or impaired AV dialysis access utilizes direct open access to the conduit and contiguous vessels. Mechanical fragmentation and surgical removal of occlusive thrombotic material is effected under direct visualization. Adjunctive thrombolytic pharmacotherapy may be employed. Residual vascular stenoses or obstructive lesions are removed and corrected using standard vascular surgical techniques (e.g., CPT codes 36831, 36832, 36833). Angiography is adjunctively employed, when appropriate and medically necessary, to assess the functional integrity of afferent and efferent vessels remote from the surgical field.

  • Stents - Subject to FDA approval of specific devices, stents are covered if used as a last resort to salvage a graft or fistula. Placement of an intravascular stent (e.g. CPT codes 37205-37206) and the associated supervision and interpretation (CPT code 75960) may be appropriate in selected clinical scenarios. The following clinical scenarios are examples where a stent may be considered for payment:
    • PTA induced rupture;
    • graft salvage (e.g., PTA is unsuccessful due to elastic recoil, stenosis has recurred or less than 3 months);
    • central veins stenosis or occlusion; and
    • aneurysm or pseudoaneurysm is present.

Stents used under experimental protocols are not covered unless used within the Category B Investigational Device Exemption (IDE) protocol.

Limitations:

When diagnostic non-invasive vascular studies are performed to evaluate an AV access on a routine basis in the absence of signs and symptoms, the services are considered monitoring, and are not separately covered by Medicare.

In the absence of clinical findings suggesting the need to re-establish appropriate flow in a dialysis fistula, it is seldom reasonable and necessary to perform diagnostic angiography or sonographic confirmatory studies as part of the decision to treat (i.e., CPT codes 75710, 75820, 93990).

Venography codes may be reported in conjunction with AV dialysis access procedures. 

Services performed for percutaneous interventions to treat total occlusion of graft due to thrombus of more than one year in duration will be considered not reasonable and not medically necessary.


Angioplasty of vessels not documented to be stenosed significantly by angiography or ultrasound will be considered not medically necessary.

Dilation of the graft anastamotic site will be considered either arterial or venous, but not both.

Use of a device that is not FDA approved will be considered investigational and not medically necessary.

Revision procedures that are not for repair and/or maintenance of an existing fistula, but are performed as part of a planned staged procedure to create a new fistula are not subject to the coverage provisions and limitations of this LCD.




Summary of Evidence

N/A

Analysis of Evidence (Rationale for Determination)

N/A

Proposed Process Information

Synopsis of Changes
Changes Fields Changed
N/A
Associated Information
Sources of Information
Bibliography
Open Meetings
Meeting Date Meeting States Meeting Information
N/A
Contractor Advisory Committee (CAC) Meetings
Meeting Date Meeting States Meeting Information
N/A
MAC Meeting Information URLs
N/A
Proposed LCD Posting Date
Comment Period Start Date
Comment Period End Date
Reason for Proposed LCD
Requestor Information
This request was MAC initiated.
Requestor Name Requestor Letter
N/A
Contact for Comments on Proposed LCD

Coding Information

Bill Type Codes

Code Description
N/A

Revenue Codes

Code Description
N/A

CPT/HCPCS Codes

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1

Group 1 Paragraph:

N/A

Group 1 Codes:

N/A

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Group 1 Paragraph:

N/A

Group 1 Codes:

N/A

N/A

Additional ICD-10 Information

General Information

Associated Information
N/A
Sources of Information
This bibliography presents those sources that were obtained during the development of this policy. CGS Administrators, LLC. is not responsible for the continuing viability of Web site addresses listed below.

American Society of Diagnostic & Interventional Nephrology. Coding of Procedures in Interventional Nephrology 2010. Release Date: 12/23/2009.

Hoggard J, Saad T, Schon D, Vesely M, Royer T. Guidelines for venous access in patients with chronic kidney disease. A position statement from the American Society of Diagnostic and Interventional Nephrology Clinical Practice Committee and the Association for Vascular Access. Seminars in Dialysis. 2008;21(2):186-191.

Murad MH, Elamin MB, Sidawy AN et al. Autogenous versus prosthetic vascular access for hemodialysis: A systematic review and meta-analysis. J Vasc Surg. 2008;48:34S-47S.

Murad MH, Swiglo BA, Sidawy AN, Ascher E, Montori VM. Methodology for clinical practice guidelines for the management of arteriovenous access. J Vasc Surg. 2008;48:26S-30S.

NKF-DOQI Clinical practice guidelines and clinical practice recommendations. 2006 updates hemodialysis adequacy, peritoneal dialysis adequacy, vascular access. http://www.kidney.org/professionals/kdoqui/guideline upHD PD VA/va guide5.htm. Accessed 11/11/2009.

Padberg FT, Calligaro KD, Sidawy AN. Complications of arteriovenous hemodialysis access: recognition and management. J Vasc Surg. 2008;48:55S-80S.

Siday AN, Spergel LM, Besarab A, et al. The Society for Vascular Surgery: Clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access. J Vasc Surg. 2008;48:2S-25S.

Society of Interventional Radiology. Interventional radiology grand rounds. Topic: preservation of hemodialysis access 2004. http://www.SIRweb.org. Accessed 11/11/2009.

Vazquez MR. Vascular access for dialysis: recent lessons and new insights. Current Opinion in Nephrology and Hypertension. 2009:18:116-121.

Vessly TM, Beathard G, Ash S, Hoggard J, Schon, for the ASDIN Clinical Practice Committee. Classification of complications associated with hemodialysis vascular access procedures. A position statement from the American Society of Diagnostic and Interventional Nephrology. Seminars in Dialysis. 2007;20(4):359-364.
Bibliography

N/A

Revision History Information

Revision History Date Revision History Number Revision History Explanation Reasons for Change
02/09/2023 R26

R26

Revision Effective: 02/09/2023

Revision Explanation: Annual Review, no changes made.

01/03/2023: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
02/10/2022 R25

R25

Revision Effective: 02/10/2022

Revision Explanation: Annual Review, removed extensive coding information in the LCD.

02/01/2022: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
02/10/2022 R24

R24

Revision Effective: 02/10/2022

Revision Explanation: Annual Review, no changes

1/31/2022: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
01/28/2021 R23

R23

Revision Effective: 01/28/2021

Revision Explanation: Annual Review, no changes

1/22/2021: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
09/19/2019 R22

R22

Revision Effective: N/A

Revision Explanation: Annual Review, no changes

1/28/2020:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
09/19/2019 R21

R21

Revision Effective: 09/19/2019 Revision Explanation: Converted policy into new policy template that no longer includes coding section based on CR 10901. For Approval, no changes.

09/13/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To Code Removal
09/19/2019 R20

R20

Revision Effective: 09/19/2019 Revision Explanation: Converted policy into new policy template that no longer includes coding section based on CR 10901.

09/12/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To Code Removal
04/04/2019 R19

R19
Revision Effective: 04/04/2019
Revision Explanation: Removed all billing and coding details from policy into related Billing and Coding article. Coding information was removed based on CR10901. 

03/29/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Removed coding based on CR10901)
01/01/2018 R18

R18

Revision Effective Date: N/A

Revision Explanation: Annual review no changes made

1/28/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
01/01/2018 R17

Revision #:R17
Revision Effective Date: N/A
Revision Explanation: Annual review no changes made

1/30/2018:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
01/01/2018 R16

Revision #:R16
Revision Effective Date: 01/01/2018
Revision Explanation: During annual HCPCS review 36120 was end dated 12/31/2017 and 36140 had a description change to include upper and lower extremity.

12/20/2017:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To CPT/HCPCS Code Changes
01/01/2017 R15 Revision #:R15
Revision Effective Date: N/A
Revision Explanation: annual review code 36906 was left out in the group 1 paragraph above the ICD-10 codes.
  • Typographical Error
01/01/2017 R14 Revision #:R14
Revision Effective Date: 01/01/2017
Revision Explanation: During annual HCPCS review codes 35475, 35476, 36147, 36148, 36870, 75791, 75962, 75964, and 75978 were deleted and replaced with 36901-36907 and 37246-37249.
  • Revisions Due To CPT/HCPCS Code Changes
01/01/2016 R13 Revision #:R13
Revision Effective Date: 01/01/2016
Revision Explanation: Added the codes above group one ICD-10 code that pertain to this list of medical necessity ICD-10 codes.
  • Reconsideration Request
01/01/2016 R12 Revision #:R12
Revision Effective Date: 01/01/2016
Revision Explanation: Added I97.89 to group two for 93990.
  • Reconsideration Request
01/01/2016 R11 Revision #:R11
Revision Effective Date: 01/01/2016
Revision Explanation: Add group two for CPT 93990 medical necessity.
  • Provider Education/Guidance
01/01/2016 R10 Revision #:R10
Revision Effective Date: 01/01/2016
Revision Explanation: Upon review of this LCD it was determined to remove the note in paragraph section for group one in the covered ICD-10 for medical necessity as CPT code 93990 applies to AV fistulas and this policy is more in line for the use of the code than he Non-Invasive Vascular Studies policy.
  • Provider Education/Guidance
01/01/2016 R9 Revision #:R9
Revision Effective Date: 01/01/2016
Revision Explanation: Added ICD-10 I77.0 to medical necessary diagnosis.
  • Reconsideration Request
01/01/2016 R8 Revision #:R8
Revision Effective Date: N/A
Revision Explanation: Bill type codes disappeared and had to add back.
  • Other (TOB codes disappeared )
01/01/2016 R7 Revision #:R7
Revision Effective Date: N/A
Revision Explanation: Annual review no changes made.
  • Other (Annual Review)
01/01/2016 R6 Revision #:R6
Revision Effective Date: 01/01/2016
Revision Explanation: CPT code 75896 deleted for 2015 and replaced with codes 37211-37214 that were already included in the policy.
  • Revisions Due To CPT/HCPCS Code Changes
10/01/2015 R5 Revision #:R5
Revision Effective Date: 10/01/2015
Revision Explanation: Added N18.6 and Z99.2 to ICD-10 diagnosis effective 10/01/2015.
  • Reconsideration Request
10/01/2015 R4 Revision #:R4
Revision Effective Date: 10/01/2015
Revision Explanation: Added paragraph at end of limitation section concerning stage procedure for fistula.
  • Provider Education/Guidance
10/01/2015 R3 Revision #:R3
Revision Effective Date: 10/01/2015
Revision Explanation: Accepted revenue code descriptions.
  • Other (revenue code)
10/01/2015 R2 Revision #:R2
Revision Effective Date: 10/01/2015
Revision Explanation: Accepted 2015 HCPCS description change for 37214 and 75791.
  • Revisions Due To CPT/HCPCS Code Changes
10/01/2015 R1 Revision #: R1
Revision Effective: N/A
Revsion Explanation: Third quarter 2014 HCPCS code description change for 37236.
  • Revisions Due To CPT/HCPCS Code Changes
N/A

Associated Documents

Attachments
N/A
Related Local Coverage Documents
Articles
A56460 - Billing and Coding: Dialysis Access Maintenance
Related National Coverage Documents
N/A
Public Versions
Updated On Effective Dates Status
01/25/2024 02/01/2024 - N/A Currently in Effect View
01/31/2023 02/09/2023 - 01/31/2024 Superseded You are here
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A

Read the LCD Disclaimer